INTERESTED IN THIS RESEARCH?
Contact our analysts for inquiries, samples, and expert insights.
Report Outlook
| Market Size | CAGR | Dominating Region |
|---|---|---|
| USD 301.6 Billion by 2029 | 14% | North America |
| By Type | By Application | By End-User Industry | By Region |
|---|---|---|---|
|
|
|
|
SCOPE OF THE REPORT
Cancer Immunotherapy Market Overview
The global Cancer Immunotherapy market is designed to grow at 14 % CAGR from 2023 to 2029. It is expected to reach above USD 301.6 Billion by 2029 from USD 105.70 Billion in 2022.
Cancer immunotherapy treatment is used to improve the immune system’s ability to fight cancer. This treatment has fewer side effects than the old technology and provides long-term cancer protection and can be treated with a wider range of cancer. It is used for different types of cancer treatment such as melanoma, breast cancer, lung cancer, prostate cancer, colorectal cancer, head, and neck cancer, and more. This targets the immune system toward cancer, activates the immune system to assemble the target, and triggers the destruction of cancer cells.
There are many factors such as rising costs, increasing incidence of cancer, increasing access to health insurance, increasing technological advancements in cancer treatment, etc. are expected to boost the growth of the global cancer immunotherapy market. According to National Cancer Institute statistics, an estimated number of new cancers were diagnosed in the United States in 2020 and died from the disease. This increase in cancer cases will boost the growth of the industry in the coming years.
Awareness programs on the need for cancer immunotherapy are expected to help the market stand out during the forecast period. However, factors such as stringent regulations related to cancer immunotherapy are expected to hinder the growth of the cancer immunotherapy market. As the government is more closely monitoring immunotherapy applications and also controls clinical trials conducted using government standards, it is difficult for companies to enter the industry, thus slowing the growth of the market. High product development costs are also expected to hinder the growth of the cancer immunotherapy market.
| ATTRIBUTE | DETAILS |
| Study period | 2020-2029 |
| Base year | 2021 |
| Estimated year | 2022 |
| Forecasted year | 2022-2029 |
| Historical period | 2018-2020 |
| Unit | Value (USD Billion) |
| Segmentation | By type, application, End-user industry, and region. |
| By Type
 |
|
| By Application
 |
|
| By End-user industry
 |
|
| By Region
 |
|
Increasing funding for the improvement of novel treatments to improve cancer immunotherapy treatment is projected to grow R&D activities. Increasing approvals for novel treatments are likely to help the cancer immunotherapy market more than the forecasted period. Leading companies are focusing on new strategies and this leads to growing the market more than the forecasted period.
The cancer immunotherapy market is divided into 3 segments type by application and by the end user. By type monoclonal antibodies hold the largest share of the market. They are leading because they reveal different properties of the immune system and they can be activated or stops the molecules in the system. In accumulation, they also provide the service for antitumor immune response.
Due to covid-19, the market is affected on a serious note. In arrears of pandemic the manufacturing and transportation are stopped. The researchers are also fewer due to lockdown limitations. This leads to less R&D work. The market witnessed the break of new medicines. Also, the consumer’s outdoor activities are reduced due to covid-19 limitations. This impacts the market growth.
However, the side effects that happen due to immunotherapy are expected to hinder the recommendation for cancer treatment. The available treatments are associated with many effects such as insomnia, pain, fatigue, nausea, and gastrointestinal conditions. These effects make cancer patients unsatisfied and lead to lower demand for cancer immunotherapy treatments.
Cancer Immunotherapy Market Segment Analysis
By application to the cancer immunotherapy market is devised into Lung, Breast, Colorectal, Melanoma, Prostate, Head, and Neck. The lung cancer market held the largest share in 2021 and is expected to hold the same position in the forecasted period also. This is leading due to awareness about cancer in people and the need for therapeutics treatment of lung cancer.
Based on end-user, we can divide the market into 3 segments. Hospitals, cancer treatment research centers, and clinics. In this region, hospitals held the largest share of the market due to the widespread use of cancer immunotherapy treatment in hospitals.
Furthermore, the use of this treatment in hospitals is helping the market to grow faster than the forecasted period. It is expected that the hospital’s region will grow at 14.7% CAGR within the forecasted period. North America is expected to hold the market as they are developing new cancer treatment technologies. Their government also taking the initiative to help cancer treatment research centers to develop new technologies as well as asking the key players to help these technologies by investing in their research. This initiative helps the market to grow faster.
Cancer Immunotherapy Market Players
The key players leading in the global cancer immunotherapy market include Amgen, Inc., AstraZeneca, PLC, Bayer AG, Bristol-Myers Squibb Company, Eli Lily and Company, F. Hoffmann-La Roche, Ltd. (Genentech, Inc.), Pfizer, Inc., Johnson &Johnson (Janssen Global Services, LLC), Merck KGAA, and Novartis AG
For corporate expansion, these key leaders are implementing strategic formulations such as new medicine development and commercialization, commercial expansion, and distribution agreements. Moreover, these participants are substantially spending on product development, which is fueling revenue generation.
Recent Developments:
- FEB 2023 – NAMMI’S cancer immunotherapy technology received two awards for its technology. NAMMI is awarded for the technology that targets only the specific part of cancer cells without targeting the whole body’s immune system. This technology would be the first to locate cancer cells in cancerous tumors which is very difficult without this technology.
- DEC 2022 – Immunotherapy is a hope for cancer warriors. Now Immunotherapy can be used for breast, head, neck, and cancerous tumors. This news will become a ray of hope for cancer warriors and hospitals also.
 Who Should Buy? Or Key Stakeholders
- Investors
- Technology Companies
- Research Organizations
- Hospitals
- Cancer treatment research centers
- Clinics
- Regulatory Authorities
- Institutional & retail players
- Others
Cancer Immunotherapy Market Regional Analysis
The cancer immunotherapy market by region includes North America, Asia-Pacific (APAC), Europe, South America, and Middle East & Africa (MEA).
- North America: includes the US, Canada, Mexico
- Asia Pacific: includes China, Japan, South Korea, India, Australia, ASEAN, and the Rest of APAC
- Europe: includes the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe
- South America: includes Brazil, Argentina, and the Rest of South America
- Middle East & Africa: includes Turkey, UAE, Saudi Arabia, South Africa, and the Rest of MEA
North America is going to be the dominant region in this market having all the facilities for research in cancer treatment technologies. They are having excellent technologies to trigger the immune system. The high demand for treatment and higher recovery of patients is growing the cancer immunotherapy market. The government also helps the market to grow by taking the initiative by investing in this technology as well as promoting it. The growth of bioinformatics tools is enhancing the drug development process. Those dynamics are helping North America to hold the market.
During the projected period, the Asia- Pacific region is anticipated to generate the second-highest amount of revenue. This might be ascribed to the rising numbers of cancer patients and the need for this technology in hospitals to cure patients. The expansion of the market is anticipated to be driven by the use of hospitals, clinics, and cancer treatment research centers.
Key Market Segments: Cancer Immunotherapy Market
Cancer Immunotherapy Market By Type, 2022-2029, (USD Billion)
- Monoclonal Antibodies
- Cancer Vaccines
- Checkpoint Inhibitors
- Immunomodulatory
Cancer Immunotherapy Market Application, 2022-2029, (USD Billion)
- Hospitals
- Lung
- Breast
- Colorectal
- Melanoma
- Prostate
- Head
- Neck
Cancer Immunotherapy Market By End-User Industry, 2022-2029, (USD Billion)
- Hospitals
- Cancer Treatment Research Centers
- Clinics
Cancer Immunotherapy Market By Region, 2022-2029, (USD Billion)
- North America
- Asia Pacific
- Europe
- South America
- Middle East and Africa
Important Countries in All Regions Are Covered.
Exactitude Consultancy Services Key Objectives:
- Increasing sales and market share
- Developing new technology
- Improving profitability
- Entering new markets
- Enhancing brand reputation
Key Question Answered
- What is the expected growth rate of the cancer immunotherapy market over the next 7 years?
- What are the end-user industries driving demand for the cancer immunotherapy market and what is their outlook?
- What are the opportunities for growth in emerging markets such as Asia-Pacific, the Middle East, and Africa?
- How is the economic environment affecting the cancer immunotherapy market, including factors such as interest rates, inflation, and exchange rates?
- What is the expected impact of government policies and regulations on the cancer immunotherapy market?
- What are the key drivers of growth in the cancer immunotherapy market?
- Who are the market’s major players, and what is their market share?
- What are the cancer immunotherapy market’s distribution channels and supply chain dynamics?
- What are the technological advancements and innovations in the cancer immunotherapy market and their impact on product development and growth?
- What are the regulatory considerations and their impact on the market?
- What are the challenges faced by players in the cancer immunotherapy market and how are they addressing these challenges?
- What are the opportunities for growth and expansion in the cancer immunotherapy market?
Table of Content
- Introduction
- Market Definition
- Market Segmentation
- Research Timelines
- Assumptions and Limitations
- Research Methodology
- Data Mining
- Secondary Research
- Primary Research
- Subject-Matter Experts’ Advice
- Quality Checks
- Final Review
- Data Triangulation
- Bottom-Up Approach
- Top-Down Approach
- Research Flow
- Data Sources
- Data Mining
- Executive Summary
- Market Overview
- Global Cancer Immunotherapy Market Outlook
- Market Drivers
- Market Restraints
- Market Opportunities
- Impact of Covid-19 on the Cancer Immunotherapy Market
- Porter’s five forces model
- Threat from new entrants
- Threat from substitutes
- Bargaining power of suppliers
- Bargaining power of customers
- Degree of competition
- Industry value chain Analysis
- Global Cancer Immunotherapy Market Outlook
- Global Cancer Immunotherapy Market by Type, 2022-2029, (USD BILLION),
- Monoclonal Antibodies
- Cancer Vaccines
- Checkpoint Inhibitors
- Immunomodulatory
- Global Cancer Immunotherapy Market by Application, 2022-2029, (USD BILLION)
- Hospital
- Lung
- Breast
- Head
- Neck
- Colorectal
- Melanoma
- Prostate
- Global Cancer Immunotherapy Market by End-user industry, 2022-2029, (USD BILLION)
- Hospital
- Clinics
- Cancer treatment research centers
- Global Cancer Immunotherapy Market by Region, 2022-2029, (USD BILLION)
- North America
- US
- Canada
- Mexico
- South America
- BRAZIL’S
- Argentina
- Colombia
- Rest Of South America
- Europe
- GERMAN
- UK
- France
- ITALY’S
- SPAIN’S
- Russia
- Rest Of Europe
- THE ASIA Pacific
- India
- China
- Japan
- South KOREAN
- AUSTRALIAN
- South-East THE ASIA
- Rest Of THE ASIA Pacific
- Middle East and Africa
- UAE
- Saudi Arabia
- South Africa
- Rest Of Middle East and Africa
- North America
- Company Profiles*
(Business Overview, Company Snapshot, Products Offered, Recent Developments)
- Amgen, Inc.
- AstraZeneca
- PLC
- Bayer AG
- Bristol-Myers Squibb Company
- Eli Lily And Company
- Hoffmann-La Roche, Ltd. (Genentech, Inc.)
- Pfizer, Inc.
- Johnson &Johnson (Janssen Global Services, LLC)
*The Company List Is Indicative
LIST OF TABLES
TABLE 1Â Â Â Â Â Â Â Â Â GLOBAL CANCER IMMUNOTHERAPY MARKET BY TYPE (USD BILLION), 2020-2029
TABLE 2Â Â Â Â Â Â Â Â Â GLOBAL CANCER IMMUNOTHERAPY MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 3Â Â Â Â Â Â Â Â Â GLOBAL CANCER IMMUNOTHERAPY MARKET BY END USER (USD BILLION), 2020-2029
TABLE 4Â Â Â Â Â Â Â Â Â GLOBAL CANCER IMMUNOTHERAPY MARKET BY REGION (USD BILLION), 2020-2029
TABLE 5Â Â Â Â Â Â Â Â Â NORTH AMERICA CANCER IMMUNOTHERAPY MARKET BY TYPE (USD BILLION), 2020-2029
TABLE 6Â Â Â Â Â Â Â Â Â NORTH AMERICA CANCER IMMUNOTHERAPY MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 7Â Â Â Â Â Â Â Â Â NORTH AMERICA CANCER IMMUNOTHERAPY MARKET BY END USER (USD BILLION), 2020-2029
TABLE 8Â Â Â Â Â Â Â Â Â NORTH AMERICA CANCER IMMUNOTHERAPY MARKET BY COUNTRY (USD BILLION), 2020-2029
TABLE 9Â Â Â Â Â Â Â Â Â US CANCER IMMUNOTHERAPY MARKET BY TYPE (USD BILLION), 2020-2029
TABLE 10Â Â Â Â Â Â Â US CANCER IMMUNOTHERAPY MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 11Â Â Â Â Â Â Â US CANCER IMMUNOTHERAPY MARKET BY END USER (USD BILLION), 2020-2029
TABLE 12Â Â Â Â Â Â Â CANADA CANCER IMMUNOTHERAPY MARKET BY TYPE (BILLION), 2020-2029
TABLE 13Â Â Â Â Â Â Â CANADA CANCER IMMUNOTHERAPY MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 14Â Â Â Â Â Â Â CANADA CANCER IMMUNOTHERAPY MARKET BY END USER (USD BILLION), 2020-2029
TABLE 15Â Â Â Â Â Â Â MEXICO CANCER IMMUNOTHERAPY MARKET BY TYPE (USD BILLION), 2020-2029
TABLE 16Â Â Â Â Â Â Â MEXICO CANCER IMMUNOTHERAPY MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 17Â Â Â Â Â Â Â MEXICO CANCER IMMUNOTHERAPY MARKET BY END USER (USD BILLION), 2020-2029
TABLE 18Â Â Â Â Â Â Â REST OF NORTH AMERICA CANCER IMMUNOTHERAPY MARKET BY TYPE (USD BILLION), 2020-2029
TABLE 19Â Â Â Â Â Â Â REST OF NORTH AMERICA CANCER IMMUNOTHERAPY MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 20Â Â Â Â Â Â Â REST OF NORTH AMERICA CANCER IMMUNOTHERAPY MARKET BY END USER (USD BILLION), 2020-2029
TABLE 21Â Â Â Â Â Â Â SOUTH AMERICA CANCER IMMUNOTHERAPY MARKET BY TYPE (USD BILLION), 2020-2029
TABLE 22Â Â Â Â Â Â Â SOUTH AMERICA CANCER IMMUNOTHERAPY MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 23Â Â Â Â Â Â Â SOUTH AMERICA CANCER IMMUNOTHERAPY MARKET BY END USER (USD BILLION), 2020-2029
TABLE 24Â Â Â Â Â Â Â SOUTH AMERICA CANCER IMMUNOTHERAPY MARKET BY COUNTRY (USD BILLION), 2020-2029
TABLE 25Â Â Â Â Â Â Â BRAZIL CANCER IMMUNOTHERAPY MARKET BY TYPE (USD BILLION), 2020-2029
TABLE 26Â Â Â Â Â Â Â BRAZIL CANCER IMMUNOTHERAPY MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 27Â Â Â Â Â Â Â BRAZIL CANCER IMMUNOTHERAPY MARKET BY END USER (USD BILLION), 2020-2029
TABLE 28Â Â Â Â Â Â Â ARGENTINA CANCER IMMUNOTHERAPY MARKET BY TYPE (USD BILLION), 2020-2029
TABLE 29Â Â Â Â Â Â Â ARGENTINA CANCER IMMUNOTHERAPY MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 30Â Â Â Â Â Â Â ARGENTINA CANCER IMMUNOTHERAPY MARKET BY END USER (USD BILLION), 2020-2029
TABLE 31Â Â Â Â Â Â Â COLOMBIA CANCER IMMUNOTHERAPY MARKET BY TYPE (USD BILLION), 2020-2029
TABLE 32Â Â Â Â Â Â Â COLOMBIA CANCER IMMUNOTHERAPY MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 33Â Â Â Â Â Â Â COLOMBIA CANCER IMMUNOTHERAPY MARKET BY END USER (USD BILLION), 2020-2029
TABLE 34Â Â Â Â Â Â Â REST OF SOUTH AMERICA CANCER IMMUNOTHERAPY MARKET BY TYPE (USD BILLION), 2020-2029
TABLE 35Â Â Â Â Â Â Â REST OF SOUTH AMERICA CANCER IMMUNOTHERAPY MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 36Â Â Â Â Â Â Â REST OF SOUTH AMERICA CANCER IMMUNOTHERAPY MARKET BY END USER (USD BILLION), 2020-2029
TABLE 37Â Â Â Â Â Â Â ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET BY TYPE (USD BILLION), 2020-2029
TABLE 38Â Â Â Â Â Â Â ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 39Â Â Â Â Â Â Â ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET BY END USER (USD BILLION), 2020-2029
TABLE 40Â Â Â Â Â Â Â ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET BY COUNTRY (USD BILLION), 2020-2029
TABLE 41Â Â Â Â Â Â Â INDIA CANCER IMMUNOTHERAPY MARKET BY TYPE (USD BILLION), 2020-2029
TABLE 42Â Â Â Â Â Â Â INDIA CANCER IMMUNOTHERAPY MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 43Â Â Â Â Â Â Â INDIA CANCER IMMUNOTHERAPY MARKET BY END USER (USD BILLION), 2020-2029
TABLE 44Â Â Â Â Â Â Â CHINA CANCER IMMUNOTHERAPY MARKET BY TYPE (USD BILLION), 2020-2029
TABLE 45Â Â Â Â Â Â Â CHINA CANCER IMMUNOTHERAPY MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 46Â Â Â Â Â Â Â CHINA CANCER IMMUNOTHERAPY MARKET BY END USER (USD BILLION), 2020-2029
TABLE 47Â Â Â Â Â Â Â JAPAN CANCER IMMUNOTHERAPY MARKET BY TYPE (USD BILLION), 2020-2029
TABLE 48Â Â Â Â Â Â Â JAPAN CANCER IMMUNOTHERAPY MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 49Â Â Â Â Â Â Â JAPAN CANCER IMMUNOTHERAPY MARKET BY END USER (USD BILLION), 2020-2029
TABLE 50Â Â Â Â Â Â Â SOUTH KOREA CANCER IMMUNOTHERAPY MARKET BY TYPE (USD BILLION), 2020-2029
TABLE 51Â Â Â Â Â Â Â SOUTH KOREA CANCER IMMUNOTHERAPY MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 52Â Â Â Â Â Â Â SOUTH KOREA CANCER IMMUNOTHERAPY MARKET BY END USER (USD BILLION), 2020-2029
TABLE 53Â Â Â Â Â Â Â AUSTRALIA CANCER IMMUNOTHERAPY MARKET BY TYPE (USD BILLION), 2020-2029
TABLE 54Â Â Â Â Â Â Â AUSTRALIA CANCER IMMUNOTHERAPY MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 55Â Â Â Â Â Â Â AUSTRALIA CANCER IMMUNOTHERAPY MARKET BY END USER (USD BILLION), 2020-2029
TABLE 56Â Â Â Â Â Â Â REST OF ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY TYPE (USD BILLION), 2020-2029
TABLE 57Â Â Â Â Â Â Â REST OF ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 58Â Â Â Â Â Â Â REST OF ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY END USER (USD BILLION), 2020-2029
TABLE 59Â Â Â Â Â Â Â EUROPE CANCER IMMUNOTHERAPY MARKET BY TYPE (USD BILLION), 2020-2029
TABLE 60Â Â Â Â Â Â Â EUROPE CANCER IMMUNOTHERAPY MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 61Â Â Â Â Â Â Â EUROPE CANCER IMMUNOTHERAPY MARKET BY END USER (USD BILLION), 2020-2029
TABLE 62Â Â Â Â Â Â Â EUROPE CANCER IMMUNOTHERAPY MARKET BY COUNTRY (USD BILLION), 2020-2029
TABLE 63Â Â Â Â Â Â Â GERMANY CANCER IMMUNOTHERAPY MARKET BY TYPE (USD BILLION), 2020-2029
TABLE 64Â Â Â Â Â Â Â GERMANY CANCER IMMUNOTHERAPY MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 65Â Â Â Â Â Â Â GERMANY CANCER IMMUNOTHERAPY MARKET BY END USER (USD BILLION), 2020-2029
TABLE 66Â Â Â Â Â Â Â UK CANCER IMMUNOTHERAPY MARKET BY TYPE (USD BILLION), 2020-2029
TABLE 67Â Â Â Â Â Â Â UK CANCER IMMUNOTHERAPY MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 68Â Â Â Â Â Â Â UK CANCER IMMUNOTHERAPY MARKET BY END USER (USD BILLION), 2020-2029
TABLE 69Â Â Â Â Â Â Â FRANCE CANCER IMMUNOTHERAPY MARKET BY TYPE (USD BILLION), 2020-2029
TABLE 70Â Â Â Â Â Â Â FRANCE CANCER IMMUNOTHERAPY MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 71Â Â Â Â Â Â Â FRANCE CANCER IMMUNOTHERAPY MARKET BY END USER (USD BILLION), 2020-2029
TABLE 72Â Â Â Â Â Â Â ITALY CANCER IMMUNOTHERAPY MARKET BY TYPE (USD BILLION), 2020-2029
TABLE 73Â Â Â Â Â Â Â ITALY CANCER IMMUNOTHERAPY MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 74Â Â Â Â Â Â Â ITALY CANCER IMMUNOTHERAPY MARKET BY END USER (USD BILLION), 2020-2029
TABLE 75Â Â Â Â Â Â Â SPAIN CANCER IMMUNOTHERAPY MARKET BY TYPE (USD BILLION), 2020-2029
TABLE 76Â Â Â Â Â Â Â SPAIN CANCER IMMUNOTHERAPY MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 77Â Â Â Â Â Â Â SPAIN CANCER IMMUNOTHERAPY MARKET BY END USER (USD BILLION), 2020-2029
TABLE 78Â Â Â Â Â Â Â RUSSIA CANCER IMMUNOTHERAPY MARKET BY TYPE (USD BILLION), 2020-2029
TABLE 79Â Â Â Â Â Â Â RUSSIA CANCER IMMUNOTHERAPY MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 80Â Â Â Â Â Â Â RUSSIA CANCER IMMUNOTHERAPY MARKET BY END USER (USD BILLION), 2020-2029
TABLE 81Â Â Â Â Â Â Â REST OF EUROPE CANCER IMMUNOTHERAPY MARKET BY TYPE (USD BILLION), 2020-2029
TABLE 82Â Â Â Â Â Â Â REST OF EUROPE CANCER IMMUNOTHERAPY MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 83Â Â Â Â Â Â Â REST OF EUROPE CANCER IMMUNOTHERAPY MARKET BY END USER (USD BILLION), 2020-2029
TABLE 84Â Â Â Â Â Â Â MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET BY TYPE (USD BILLION), 2020-2029
TABLE 85Â Â Â Â Â Â Â MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 86Â Â Â Â Â Â Â MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET BY END USER (USD BILLION), 2020-2029
TABLE 87Â Â Â Â Â Â Â MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET BY COUNTRY (USD BILLION), 2020-2029
TABLE 88Â Â Â Â Â Â Â UAE CANCER IMMUNOTHERAPY MARKET BY TYPE (USD BILLION), 2020-2029
TABLE 89Â Â Â Â Â Â Â UAE CANCER IMMUNOTHERAPY MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 90Â Â Â Â Â Â Â UAE CANCER IMMUNOTHERAPY MARKET BY END USER (USD BILLION), 2020-2029
TABLE 91Â Â Â Â Â Â Â SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET BY TYPE (USD BILLION), 2020-2029
TABLE 92Â Â Â Â Â Â Â SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 93Â Â Â Â Â Â Â SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET BY END USER (USD BILLION), 2020-2029
TABLE 94Â Â Â Â Â Â Â SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET BY TYPE (USD BILLION), 2020-2029
TABLE 95Â Â Â Â Â Â Â SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 96Â Â Â Â Â Â Â SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET BY END USER (USD BILLION), 2020-2029
TABLE 97Â Â Â Â Â Â Â REST OF MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET BY TYPE (USD BILLION), 2020-2029
TABLE 98Â Â Â Â Â Â Â REST OF MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 99Â Â Â Â Â Â Â REST OF MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET BY END USER (USD BILLION), 2020-2029
LIST OF FIGURES
FIGURE 1Â Â Â Â Â Â Â Â Â Â Â Â Â MARKET DYNAMICS
FIGURE 2Â Â Â Â Â Â Â Â Â Â Â Â Â MARKET SEGMENTATION
FIGURE 3Â Â Â Â Â Â Â Â Â Â Â Â Â REPORT TIMELINES: YEARS CONSIDERED
FIGURE 4Â Â Â Â Â Â Â Â Â Â Â Â Â DATA TRIANGULATION
FIGURE 5Â Â Â Â Â Â Â Â Â Â Â Â Â BOTTOM-UP APPROACH
FIGURE 6Â Â Â Â Â Â Â Â Â Â Â Â Â TOP-DOWN APPROACH
FIGURE 7Â Â Â Â Â Â Â Â Â Â Â Â Â RESEARCH FLOW
FIGURE 8Â Â Â Â Â Â Â Â Â Â Â Â Â GLOBAL CANCER IMMUNOTHERAPY MARKET BY TYPE, USD BILLION, 2022-2029
FIGURE 9Â Â Â Â Â Â Â Â Â Â Â Â Â GLOBAL CANCER IMMUNOTHERAPY MARKET BY APPLICATION, USD BILLION, 2022-2029
FIGURE 10Â Â Â Â Â Â Â Â Â Â GLOBAL CANCER IMMUNOTHERAPY MARKET BY END USER, USD BILLION, 2022-2029
FIGURE 11Â Â Â Â Â Â Â Â Â Â GLOBAL CANCER IMMUNOTHERAPY MARKET BY REGION, USD BILLION, 2022-2029
FIGURE 12          PORTER’S FIVE FORCES MODEL
FIGURE 13Â Â Â Â Â Â Â Â Â Â GLOBAL CANCER IMMUNOTHERAPY MARKET BY TYPE, 2020
FIGURE 14Â Â Â Â Â Â Â Â Â Â GLOBAL CANCER IMMUNOTHERAPY MARKET BY APPLICATION 2020
FIGURE 15Â Â Â Â Â Â Â Â Â Â GLOBAL CANCER IMMUNOTHERAPY MARKET BY END USER 2020
FIGURE 16Â Â Â Â Â Â Â Â Â Â CANCER IMMUNOTHERAPY MARKET BY REGION 2020
FIGURE 17Â Â Â Â Â Â Â Â Â Â MARKET SHARE ANALYSIS
FIGURE 18Â Â Â Â Â Â Â Â Â Â AMAGEN INC: COMPANY SNAPSHOT
FIGURE 19Â Â Â Â Â Â Â Â Â Â PLC: COMPANY SNAPSHOT
FIGURE 20Â Â Â Â Â Â Â Â Â Â BAYER AG: COMPANY SNAPSHOT
FIGURE 21Â Â Â Â Â Â Â Â Â Â ASTRAZENECA: COMPANY SNAPSHOT
FIGURE 22Â Â Â Â Â Â Â Â Â Â ELI LILY AND COMPANY: COMPANY SNAPSHOT
FIGURE 23Â Â Â Â Â Â Â Â Â Â BRISTOL MAYER SQUIB COMPANY: COMPANY SNAPSHOT
FIGURE 24Â Â Â Â Â Â Â Â Â Â F. HOFFMAN LA RUCHE: COMPANY SNAPSHOT
FIGURE 25Â Â Â Â Â Â Â Â Â Â P FIZER INC: COMPANY SNAPSHOT
FAQ
The market value for cancer immunotherapy market rate is expected to reach USD 301.66 Billion over the next 7 years.
Growing demand for the cancer immunotherapy market by end-user industries are hospitals, clinics, and cancer treatment research centers. And their outlook is to develop a technology that will trigger the immune system and inhibits cancer growth.
The government taking the initiative to develop cancer immunotherapy treatment and also releasing funds for research work on cancer treatment technologies. This move taken by the government is making the cancer immunotherapy market grow.
The market’s largest share is in the North American region.
In-Depth Database
Our Report’s database covers almost all topics of all regions over the Globe.
Recognised Publishing Sources
Tie ups with top publishers around the globe.
Customer Support
Complete pre and post sales
support.
Safe & Secure
Complete secure payment
process.